Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
RCTs
RCT mortality
All outcomes

Feedback
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 sotrovimab studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 67% 1 583 Improvement, Studies, Patients Relative Risk, 95% CI Mortality 67% 1 583 Ventilation 80% 1 583 ICU admission 91% 1 583 Hospitalization 81% 1 583 RCTs 67% 1 583 Early 67% 1 583 Sotrovimab for COVID-19 c19sv.com Nov 29, 2021 Favors sotrovimab Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 67% 0.33 [0.01-8.16] death 0/291 1/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement All studies 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement 1 sotrovimab COVID-19 study c19sv.com Nov 29, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67 Effect extraction pre-specified Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 67% 0.33 [0.01-8.16] 0/291 1/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement All studies 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement 1 sotrovimab COVID-19 mortality result c19sv.com Nov 29, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 80% 0.20 [0.01-4.15] 0/291 2/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 80% 0.20 [0.01-4.15] 0/291 2/292 80% improvement All studies 80% 0.20 [0.01-4.15] 0/291 2/292 80% improvement 1 sotrovimab COVID-19 mechanical ventilation result c19sv.com Nov 29, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.04 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 91% 0.09 [0.01-1.64] 0/291 5/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 91% 0.09 [0.01-1.64] 0/291 5/292 91% improvement All studies 91% 0.09 [0.01-1.64] 0/291 5/292 91% improvement 1 sotrovimab COVID-19 ICU result c19sv.com Nov 29, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.62 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 81% 0.19 [0.07-0.55] hosp. 4/291 21/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 81% 0.19 [0.07-0.55] 4/291 21/292 81% improvement All studies 81% 0.19 [0.07-0.55] 4/291 21/292 81% improvement 1 sotrovimab COVID-19 hospitalization result c19sv.com Nov 29, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 3.07 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 67% 0.33 [0.01-8.16] death 0/291 1/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement All studies 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement 1 sotrovimab COVID-19 serious outcomes c19sv.com Nov 29, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67 Effect extraction pre-specified Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 67% 0.33 [0.01-8.16] death 0/291 1/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement All studies 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement 1 sotrovimab COVID-19 Randomized Controlled Trials c19sv.com Nov 29, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67 Effect extraction pre-specified Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 67% 0.33 [0.01-8.16] 0/291 1/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement All studies 67% 0.33 [0.01-8.16] 0/291 1/292 67% improvement 1 sotrovimab COVID-19 RCT mortality result c19sv.com Nov 29, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.67 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 67% 0.33 [0.01-8.16] death 0/291 1/292 Improvement, RR [CI] Treatment Control Gupta (DB RCT) 80% 0.20 [0.01-4.15] ventilation 0/291 2/292 Gupta (DB RCT) 91% 0.09 [0.01-1.64] ICU 0/291 5/292 Gupta (DB RCT) 81% 0.19 [0.07-0.55] hosp. 4/291 21/292 Gupta (DB RCT) 86% 0.14 [0.04-0.48] hosp. 3/291 21/292 sotrovimab COVID-19 outcomes c19sv.com Nov 29, 2021 Favors sotrovimab Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit